These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 6366131)

  • 1. High-dose VP-16-213 and autologous bone marrow transplantation for refractory malignancies: a phase I study.
    Wolff SN; Fer MF; McKay CM; Hande KR; Hainsworth JD; Greco FA
    J Clin Oncol; 1983 Nov; 1(11):701-5. PubMed ID: 6366131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose VP-16-213 monotherapy for refractory germinal malignancies: a phase II study.
    Wolff SN; Johnson DH; Hainsworth JD; Greco FA
    J Clin Oncol; 1984 Apr; 2(4):271-4. PubMed ID: 6368760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy with maximally tolerable doses of VP 16-213 and cyclophosphamide followed by autologous bone marrow transplantation for the treatment of relapsed or refractory germ cell tumors.
    Mulder PO; de Vries EG; Koops HS; Splinter T; Maas A; van der Geest S; Mulder NH; Sleijfer DT
    Eur J Cancer Clin Oncol; 1988 Apr; 24(4):675-9. PubMed ID: 2838293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose etoposide for refractory malignancies: a phase I study.
    Postmus PE; Mulder NH; Sleijfer DT; Meinesz AF; Vriesendorp R; de Vries EG
    Cancer Treat Rep; 1984 Dec; 68(12):1471-4. PubMed ID: 6509453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclophosphamide and VP 16-213 with autologous bone marrow transplantation. A dose escalation study.
    Postmus PE; de Vries EG; De Vries-Hospers HG; Vriesendorp R; van Imhoff GW; Holthuis JJ; Sibinga CT; Sleijfer DT; Mulder NH
    Eur J Cancer Clin Oncol; 1984 Jun; 20(6):777-82. PubMed ID: 6086355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I-II study of two consecutive courses of high-dose epipodophyllotoxin, ifosfamide, and carboplatin with autologous bone marrow transplantation for treatment of adult patients with solid tumors.
    Lotz JP; Machover D; Malassagne B; Hingh B; Donsimoni R; Gumus Y; Gerota J; Lam Y; Tulliez M; Marsiglia H
    J Clin Oncol; 1991 Oct; 9(10):1860-70. PubMed ID: 1919636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I trial of high-dose melphalan, high-dose etoposide and autologous bone marrow re-infusion in solid tumors: an Eastern Cooperative Oncology Group (ECOG) study.
    Lazarus HM; Gray R; Ciobanu N; Winter J; Weiner RS
    Bone Marrow Transplant; 1994 Sep; 14(3):443-8. PubMed ID: 7994270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic daily administration of oral etoposide--a phase I trial.
    Hainsworth JD; Johnson DH; Frazier SR; Greco FA
    J Clin Oncol; 1989 Mar; 7(3):396-401. PubMed ID: 2918334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Feasibility of high dose VP 16-213 as single agent or in combination with cyclophosphamide and autologous bone marrow transplantation (ABMT).
    Mulder NH; Meinesz AF; Sleijfer DT; Postmus PE; De Vries EG; Van der Geest S; Orie JL; Vriesendorp R
    Neth J Med; 1984; 27(10):389-92. PubMed ID: 6096742
    [No Abstract]   [Full Text] [Related]  

  • 10. Phase I study of VP-16-213 (Etoposide) administered as a continuous 5-day infusion.
    Lokich J; Corkery J
    Cancer Treat Rep; 1981; 65(9-10):887-9. PubMed ID: 7273024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intensive 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), NSC #4366650 and cryopreserved autologous marrow transplantation for refractory cancer. A phase I-II study.
    Phillips GL; Fay JW; Herzig GP; Herzig RH; Weiner RS; Wolff SN; Lazarus HM; Karanes C; Ross WE; Kramer BS
    Cancer; 1983 Nov; 52(10):1792-802. PubMed ID: 6354414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of high-dose continuous intravenous infusion of VP-16 in combination with high-dose melphalan followed by autologous bone marrow transplantation in children with stage IV neuroblastoma.
    Valteau-Couanet D; Vassal G; Pondarré C; Bonnay M; Benhamou E; Couanet D; Plantaz D; Hartmann O
    Bone Marrow Transplant; 1996 Apr; 17(4):485-9. PubMed ID: 8722343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Late intensification in small-cell lung cancer: a phase I study of high doses of cyclophosphamide and etoposide with autologous bone marrow transplantation.
    Sculier JP; Klastersky J; Stryckmans P
    J Clin Oncol; 1985 Feb; 3(2):184-91. PubMed ID: 2981983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of high-dose cyclophosphamide, BCNU, and VP-16-213 followed by autologous marrow rescue in the treatment of relapsed leukemia.
    Zander AR; Vellekoop L; Spitzer G; Verma DS; Litam J; McCredie KB; Keating M; Hester JP; Dicke KA
    Cancer Treat Rep; 1981; 65(5-6):377-81. PubMed ID: 7016323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose-finding study.
    Wheeler C; Antin JH; Churchill WH; Come SE; Smith BR; Bubley GJ; Rosenthal DS; Rappaport JM; Ault KA; Schnipper LE
    J Clin Oncol; 1990 Apr; 8(4):648-56. PubMed ID: 2313334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A phase I study of VP-16-213 (VP, etoposide) by single and 5-day intravenous administration].
    Wakui A; Yokoyama M; Takahashi H; Yoshida Y; Sakata Y; Sato S; Kano A; Kawamoto K; Hashimoto S; Konno K
    Gan To Kagaku Ryoho; 1986 Feb; 13(2):319-29. PubMed ID: 3947109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose carboplatin and etoposide with autologous bone marrow transplantation in refractory germ cell cancer: an Eastern Cooperative Oncology Group protocol.
    Nichols CR; Andersen J; Lazarus HM; Fisher H; Greer J; Stadtmauer EA; Loehrer PJ; Trump DL
    J Clin Oncol; 1992 Apr; 10(4):558-63. PubMed ID: 1312584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study of high-dose etoposide phosphate in man.
    Fields SZ; Budman DR; Young RR; Kreis W; Ingram R; Schulman P; Cherny RC; Wright J; Behr J; Snow C; Schacter LP
    Bone Marrow Transplant; 1996 Nov; 18(5):851-6. PubMed ID: 8932836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose etoposide with autologous bone marrow transplantation as initial treatment of small cell lung cancer--a negative report.
    Littlewood TJ; Bentley DP; Smith AP
    Eur J Respir Dis; 1986 May; 68(5):370-4. PubMed ID: 3015650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose etoposide (VP-16) in small-cell lung cancer.
    Greco FA; Johnson DH; Hande KR; Porter LL; Hainsworth JD; Wolff SN
    Semin Oncol; 1985 Mar; 12(1 Suppl 2):42-4. PubMed ID: 2983434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.